HOME >> BIOLOGY >> NEWS
Highly specific biological agents attack mechanisms of treatment resistance

Conjugated Herceptin dramatically improves Herceptin-alone results against breast cancer

A Herceptin-DM1 conjugate produced complete regressions in mice bearing human breast cancer where Herceptin alone slowed tumor growth, according to new data presented here today.

Approximately 25% of all breast cancer patients carry extra copies of HER2, a protein that instructs their tumor to grow. Herceptin is a monoclonal antibody that binds to HER2 and suppresses its growth signal.

Were looking for ways to enhance the clinical benefit of Herceptin, such as attaching to it agents that might be synergistic, such as DM1, a compound that blocks cell division, said Ralph H. Schwall, Ph.D., senior scientist at Genentech, Inc., South San Francisco, CA, and lead author of the current study

In this study, Herceptin was chemically bound to DM1 and tested against three different experimental breast cancer systems that have extra copies of HER2. In the first two, which used human breast cancer cells growing in mice, Herceptin-DM1 resulted in the complete disappearance of all tumors, whereas Herceptin as a single agent slowed tumor growth but did not cause regression.

The third experiment used a breast tumor from a transgenic mouse engineered to have high levels of HER2. The growth of this mouse tumor did not respond to Herceptin, but Herceptin-DM1 caused the tumor to shrink by more than 90%, indicating that Herceptin-DM1 can work in a tumor that is resistant to Herceptin. Tumors began to regrow four to six weeks after the final dose of Herceptin-DM1, but regressed again when retreated with Herceptin-DM1.

Genentech manufactures Herceptin and partnered with ImmunoGen, Inc., of Cambridge, MA, to develop the linked molecule. Were pursuing additional animal studies to get a realistic safety profile of this conjugate, Dr. Schwall said.

DM1 is a member of the maytansine family of tubulin-blocking compounds. Tubuli
'"/>

Contact: Peter Vigliarolo
pvigliarolo@cwg.com
212-886-2200
American Association for Cancer Research
31-Oct-2001


Page: 1 2 3 4 5 6

Related biology news :

1. Leibniz Prize Winners 1999 - Most Highly Endowed German Promotional Prize For Ten Scientists
2. Veterans with Gulf War syndrome have damage in specific, primitive portion of nervous system
3. Resveratrol synthase uncovered: Cyclization specificity of type III polyketide synthases
4. Anticancer drug zebularine specifically targets tumor cells
5. PCB breakdown in rivers depends on sediment-specific bacteria, find Carnegie Mellon U. scientists
6. X marks the spot: Vector insertion is viral specific
7. Triple-vaccine strategy stimulates strong HIV-specific immune response in monkeys
8. Sex-specific differences in gene expression related to drug metabolism and hypertension
9. New papillomavirus target could lead to specific antiviral drugs for precancerous cervical lesions
10. Lack of specific brain protein causes marked deficits in learning, memory
11. HIV exhausts the immune system through chronic non-specific activation

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/21/2017)... N.Y. and PORTLAND, Ore. ... ) and the Avamere Family of Companies (Avamere Health ... today announced a six-month research study that will apply ... improve eldercare at senior living and health centers. By ... Avamere hopes to gain insights into physical and environmental ...
(Date:2/21/2017)... -- Der weltweite Biobanking-Sektor wird bis zum ... mit mehr als 50 Vertretern aus verschiedenen Branchen wurde aber ... diese Prognose zu realisieren. ... Zu den Schwierigkeiten für ... für die Biobank, die Implementierung Zeit sparender Technologien, ein ...
(Date:2/16/2017)... FRANCISCO , Feb. 16, 2017  Genos, ... today announced that it has received Laboratory Accreditation ... CAP Accreditation is presented to laboratories that meet ... who demonstrate scientifically rigorous processes. "Genos ... excellence in laboratory practices. We,re honored to be ...
Breaking Biology News(10 mins):
(Date:2/21/2017)... 2017 Synthetic Biologics, Inc. (NYSE MKT: SYN), ... to protect and restore the health of patients, intends to report ... 2016 on Thursday, March 2, 2017, and to host a conference ... for the call is as follows: U.S. (toll free): ... ...
(Date:2/21/2017)... , Feb. 21, 2017 /PRNewswire/ - SQI Diagnostics Inc. ("SQI" or ... operational results for the three months ended December 31, 2016. ... -based life sciences and diagnostics company that develops and commercializes ... ... to build on the commercial milestones achieved in fiscal 2016," ...
(Date:2/21/2017)... ... February 21, 2017 , ... ... to build connected digital health applications, announced a partnership with Redox, a leader ... seamlessly connect to many clinical systems while keeping data secure in the cloud. ...
(Date:2/21/2017)... PARK, CA (PRWEB) , ... February 21, 2017 ... ... of the VTX-1 Liquid Biopsy System , a fully automated benchtop system ... microfluidic technology. The VTX-1 is being launched at the Molecular Medicine Tri Conference ...
Breaking Biology Technology:
Cached News: